StockNow
Log in
U.S. Markets

Bristol Myers Squibb (BMY) Q2 2026 (USD): Adj. EPS 2.04 (exp. 1.59), Revenue 12.97bln (exp. 11.75bln)

StockNow breaking-news AI analysis

Bristol Myers Squibb beat Q2 estimates with $2.04 EPS and $12.97B revenue. It raised its 2026 guidance, supported by portfolio developments in Opdivo and AI drug discovery.

News detail

Outlook FY revenue about 49-50bln (exp. 47.47bln). FY adj. EPS 6.75-7.00 (exp. 6.34).

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

Geopolitics

The draft agreed to by Iranian and Omani negotiators awaits final approval from Iran’s supreme leader, two regional officials told The Associated Press on Wednesday